|
11/17/2008 09:00 AM
|
|
11/13/2008 03:52 PM
|
|
10/14/2008 08:23 AM
|
|
4/2/2008 05:08 PM
|
|
1/6/2008 04:00 PM
|
|
12/6/2007 09:20 PM
|
|
4/14/2007 04:49 AM
|
|
4/14/2007 04:41 AM
|
|
4/14/2007 03:29 AM
|
|
4/14/2007 03:45 AM
|
|
1/7/2007 06:13 PM
|
|
12/25/2006 05:46 PM
|
|
8/4/2006 12:44 AM
|
|
7/4/2006 03:58 AM
|
|
6/19/2006 10:46 PM
|
|
2/14/2006 04:24 PM
|
|
1/9/2006 09:17 PM
|
|
2/20/2005 05:28 PM
|
|
Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, [View Printable]
|
mwil
Group: Member Posts: 14 Joined: Jun 18, 2005
|
Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A
Yoshiko Ishida, Yasuyuki Goto, Takaaki Kondo, Mio Kurata, Kazuko Nishio, Sayo Kawai, Tomo Osafune, Mariko Naito, Nobuyuki Hamajima
Department of Preventive Medicine / Biostatistics and Medical Decision Making, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
Int J Med Sci 2006 3:135-140 http://www.medsci.org/v03p0135
Abstract
Background: Lansoprazole, amoxicillin, and clarithromycin are commonly used drugs for eradication of Helicobacter pylori (H. pylori). A few studies reported that the eradication rate was influenced by the functional polymorphism of CYP2C19, whose product metabolizes proton pomp inhibitors including lansoprazole.
Methods: This study examined the eradication rate among 67 participants in the polymorphism study who visited Daiko Medical Center, Nagoya University from July 2004 to October 2005. The participants aged 20 to 69 years were classified into three group according to CYP2C19 genotype; rapid metabolizers (RM) with *1*1 genotype, intermediate metabolizers (IM) with *1*2 or *1*3 genotype, and poor metabolizers (PM) with *2*2, *2*3, or *3*3 genotype. For the genotype classification, G681A (681G for *1 and 681A for *2) and G636A (636G for *1 and 636A for *3) were genotyped by PCR with confronting two-pair primers (PCR-CTPP). They were also genotyped for IL-1B T-31C and TNF-A T-1031C by a duplex PCR-CTPP.
Results: The eradication rate was 70.0% for RM, 93.9% for IM, and 85.7% for PM. The difference in the rate between RM and IM+PM was statistically significant (p=0.025). The eradication rate was highest for those with IL-1B -31CC; the p value was marginal among the whole subjects (χ2=3.78, p=0.05) and not significant among the RM group (χ2=1.60, p=0.21). The genotypes of TNF-A T-1031C had no associations with the eradication rate. But among the RM group, the odd ratio (OR) of the TNF-A CT for the eradication rate relative to TT was marginally reduced (OR=0.05, 95% confidence interval, 0.002-1.19).
Conclusions: The present study confirmed the low eradication rate for RM. The reproduced finding provides evidence that the CYP2C19 genotype is useful to predict the success of the treatment. For the RM group, alternative regimens expected to be with a higher eradication rate will be recommended, especially to those with the TNF-A -1031C allele.
Keywords: Helicobacter pylori, Eradication, CYP2C19, IL-1B, TNF-A
|
.........................
|
| Posted Sep 20, 2006, 23:48 PM |
|
|
|
Tracy
Group: Member Posts: 227 Joined: Feb 09, 2006
|
| mwil said: | Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A
Yoshiko Ishida, Yasuyuki Goto, Takaaki Kondo, Mio Kurata, Kazuko Nishio, Sayo Kawai, Tomo Osafune, Mariko Naito, Nobuyuki Hamajima
Department of Preventive Medicine / Biostatistics and Medical Decision Making, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
Int J Med Sci 2006 3:135-140 http://www.medsci.org/v03p0135
Abstract
Background: Lansoprazole, amoxicillin, and clarithromycin are commonly used drugs for eradication of Helicobacter pylori (H. pylori). A few studies reported that the eradication rate was influenced by the functional polymorphism of CYP2C19, whose product metabolizes proton pomp inhibitors including lansoprazole.
Methods: This study examined the eradication rate among 67 participants in the polymorphism study who visited Daiko Medical Center, Nagoya University from July 2004 to October 2005. The participants aged 20 to 69 years were classified into three group according to CYP2C19 genotype; rapid metabolizers (RM) with *1*1 genotype, intermediate metabolizers (IM) with *1*2 or *1*3 genotype, and poor metabolizers (PM) with *2*2, *2*3, or *3*3 genotype. For the genotype classification, G681A (681G for *1 and 681A for *2) and G636A (636G for *1 and 636A for *3) were genotyped by PCR with confronting two-pair primers (PCR-CTPP). They were also genotyped for IL-1B T-31C and TNF-A T-1031C by a duplex PCR-CTPP.
Results: The eradication rate was 70.0% for RM, 93.9% for IM, and 85.7% for PM. The difference in the rate between RM and IM+PM was statistically significant (p=0.025). The eradication rate was highest for those with IL-1B -31CC; the p value was marginal among the whole subjects (χ2=3.78, p=0.05) and not significant among the RM group (χ2=1.60, p=0.21). The genotypes of TNF-A T-1031C had no associations with the eradication rate. But among the RM group, the odd ratio (OR) of the TNF-A CT for the eradication rate relative to TT was marginally reduced (OR=0.05, 95% confidence interval, 0.002-1.19).
Conclusions: The present study confirmed the low eradication rate for RM. The reproduced finding provides evidence that the CYP2C19 genotype is useful to predict the success of the treatment. For the RM group, alternative regimens expected to be with a higher eradication rate will be recommended, especially to those with the TNF-A -1031C allele.
Keywords: Helicobacter pylori, Eradication, CYP2C19, IL-1B, TNF-A
|
This is very interesting.
|
.........................
|
| Posted Sep 21, 2006, 0:21 AM |
|
|
|
|
top of page
|
|
Forum Jump
|
|